FilingReader Intelligence

Leadman Biochemistry stock jumps 35% amid acquisition plan

August 9, 2025 at 05:18 AM UTCBy FilingReader AI

Beijing Leadman Biochemistry's stock jumped 34.99% over two trading days following announcement of plans to acquire up to 70% of Beijing Saimen Xiangrui Bio-Products for cash.

The company reported 2024 revenue of 370.23 million yuan but posted a net loss of 75.10 million yuan. The acquisition remains in early stages and faces potential financing challenges.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:300289Shenzhen Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Beijing Leadman Biochemistry publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →